title: Screening for aneuploidy.
abstract: Over the past 15 years, biochemical screening for chromosomal abnormalities, particularly Down's syndrome, has advanced from being extremely naive, to now somewhat more sophisticated. Sensitivities have gone from 20% to 60-70%. Considerable work is still required to not only increase the sensitivity, but also the specificity to keep health care costs down.
authors.affiliation: Center for Fetal Diagnosis and Therapy, Wayne State University, Huytzel Hospital, Detroit, MI 48201, USA.
authors.forename: M I
authors.initials: MI
authors.lastname: Evans
authors.forename: J E
authors.initials: JE
authors.lastname: O'Brien
authors.forename: A
authors.initials: A
authors.lastname: Johnson
mesh_terms: D000782:Aneuploidy; D015415:Biomarkers / Q000032:analysis; D005260:Female; D005817:Genetic Counseling / Q000639:trends; D006801:Humans; D008403:Mass Screening / Q000639:trends*; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000639:trends*; D016216:Ultrasonography, Prenatal / Q000639:trends
chemical_list: D015415:Biomarkers